background image
RCSI ANNUAL REPORT 2013-2014
30
We promote innovative research that:
>

leads to improved diagnostics,
therapeutics and devices;
>

tackles important healthcare delivery
issues;
>
informs policy and clinical practice; and,
>
enhances the quality of education
of healthcare professionals.
RCSI recognises that excellence in
research is critical to the quality of its
educational activities and its mission to
enhance human health.
COMMUNICATION OF HIGH
IMPACT RESEARCH
In this annual reporting period (July 1,
2013 to June 30, 2014), researchers at
RCSI published a total of 260 Pubmed
indexed articles, communicating
research findings in a very broad range
of health science disciplines. This is a
brief sample selected from the array of
articles published in exceptionally high
impact journals where the senior author
was an RCSI staff member.
Identifying novel gene for epilepsy
RCSI researchers and collaborators
identified a novel gene for epilepsy
along with a novel biological pathway
involved with the condition. The study,
entitled "TDP2 protects transcription
from abortive topoisomerase activity
and is required for normal neural
function" was published in Nature
genetics (2014 May, 46:516-21), and
includes RCSI authors Dr gianpiero
Cavalleri, Dr Mark McCormack and
Professor Norman Delanty.
Role of protein in treating
hereditary emphysema
Researchers from RCSI and Beaumont
Hospital made an important
breakthrough in the understanding and
treatment of hereditary emphysema.
Their exciting findings show that the
protein Alpha-1 Antitrypsin (AAT)
plays an important role in controlling
inflammation from white blood cells
and is important for good health. The
research found that AAT, when released
into the bloodstream, travels to the
lungs to protect the lung from disease.
Their research findings were published
in Science Translational Medicine
(2014 January, 6:217ra1). The joint lead
authors on the research were
Dr David Bergin and Dr Emer Reeves,
with Professor gerry McElvaney as
senior author.
Developing new anti-
diarrhoeal medication
New gastroenterology research carried
out by RCSI in conjunction with Trinity
College Dublin and Johns Hopkins
University in Baltimore, Maryland
uncovered a new route for the
development of anti-diarrhoeal drugs.
The new route directly targets cells and
molecular processes that control water
movement into the intestine and may
Professor Ray Stallings
Director of Research
RCSI
RESEARCH
RCSI's mission in research is to
improve human health through
translational research, i.e., clinical,
laboratory-based and health
service research informed by
bedside problems, societal and
global health challenges.
Pictured at the launch of "SPHeRE" (Structured Population and Health-services Research
Education) were (l-r) Mr. Enda Connolly, CEO, HRB; Professor Reinhard Busse, Technical
University of Berlin; Professor Hannah Mcgee, Dean of the Faculty of Medicine and Health
Sciences, RCSI; Professor Patricia Kearney, UCC; Professor Anne Hickey, RCSI and Director
of SPHeRE; Mr Tony O'Brien, Director general of the Health Service; and Professor Steve
Thomas, Trinity College and Co-Director of SPHeRE.